Abstract
Lipodystrophy and its two components lipo-accumulation and lipoatropy are very common among individuals with HIV infection on treatment, especially among those who started therapy in the late 1990s and early 2000s. This review discusses the current management of these complications of HIV and its treatment. For the purpose of clarity in this review, we have divided the interventions according to the predominant phenotype of the individual.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Anti-Retroviral Agents / adverse effects
-
Anti-Retroviral Agents / therapeutic use
-
Body Composition / drug effects*
-
HIV-Associated Lipodystrophy Syndrome / etiology
-
HIV-Associated Lipodystrophy Syndrome / physiopathology
-
HIV-Associated Lipodystrophy Syndrome / therapy*
-
Human Growth Hormone / therapeutic use
-
Humans
-
Insulin Resistance
-
Phenotype
Substances
-
Anti-Retroviral Agents
-
Human Growth Hormone